| | | | |
CUSIP No. 070830104 | | SCHEDULE 13D | | Page 4 of 6 Pages |
Item 1. Security and Issuer.
This Amendment No. 2 to Schedule 13D (this “Amendment No. 2”) relates to the shares of common stock, par value $0.50 per share (“Common Stock”), of Bath & Body Works, Inc. (the “Issuer”) and amends the Schedule 13D filed on December 8, 2022 (the “Original Schedule 13D”), as amended by Amendment No. 1 to Schedule 13D filed on February 22, 2023 (together, the “Schedule 13D”). Capitalized terms used and not defined in this Amendment No. 2 have the meanings set forth in the Schedule 13D.
This Amendment No. 2 is being filed to amend Item 3, Item 4, and Item 5 as follows:
Item 3. Source and Amount of Funds or Other Consideration Item 3 of the Schedule 13D is hereby amended and restated to read as follows:
The Funds expended an aggregate of approximately $524,688,070 of their own investment capital to acquire the 13,751,100 shares of Common Stock held by them.
The Reporting Persons and Funds may effect purchases of shares of Common Stock through margin accounts maintained for them with brokers, which extend margin credit as and when required to open or carry positions in their margin accounts, subject to applicable federal margin regulations, stock exchange rules and such firms’ credit policies. Positions in shares of Common Stock may be held in margin accounts and may be pledged as collateral security for the repayment of debit balances in such accounts. Such margin accounts may from time to time have debit balances. In addition, since other securities may be held in such margin accounts, it may not be possible to determine the amounts, if any, of margin used to purchase shares of Common Stock.
Item 4. Purpose of Transaction. Item 4 of the Schedule 13D is hereby amended to include the following:
On March 6, the Issuer issued a press release announcing the appointment, effective March 10, 2023, of Thomas Kuhn to the Board. Mr. Kuhn was introduced and recommended to the Issuer by the Reporting Persons. In light of the foregoing, the Reporting Persons have informed the Issuer that they no longer intend to nominate candidates to stand for election to the Board at the Issuer’s 2023 Annual Meeting of Stockholders.
Item 5. Interest in Securities of the Issuer. Items 5(a) and 5(c) of the Schedule 13D are hereby amended and restated to read as follows:
(a) On the date of this Schedule 13D, the Reporting Persons beneficially own an aggregate of 13,751,100 shares of Common Stock held by the Funds (such shares, the “Shares”). The Shares represent approximately 6.02% of the Issuer’s Common Stock outstanding. Calculations of the percentage of Common Stock beneficially owned assumes 228,414,615 shares of Common Stock outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 30, 2022.
(c) Set forth on Schedule A hereto are all transactions in the shares of Common Stock effected during the past sixty days by the Reporting Persons, inclusive of any transactions effected through 4:00 p.m., New York City time, on March 3, 2023.